This article is more than 5 years old. Information may no longer be current.
B&L reports year-end earnings
ROCHESTER, N.Y. — Bausch & Lomb increased its net sales to $2.23 billion in 2004, up 11% from 2003, the company announced in a press release. The company’s contact lens, pharmaceutical and cataract/vitreoretinal divisions all posted double-digit gains in the fourth quarter as well, the press release stated. Sales in the Americas, Europe and Asia-Pacific geographical regions increased as well, the company said.
Leading products for B&L included the SofLens line of contact lenses, the ReNu line of contact lens cleaners, and the PreserVision and Ocuvite ocular vitamins. Higher cataract/vitreoretinal sales were attributed to the increase in demand for the SofPort and Akreos IOL lines.
Lower laser sales in the Americas accounted for a decline in the company’s refractive surgery sales. B&L attributed the decline to the late 2003 launch of the Zyoptix laser system, which caused unusually high sales in the fourth quarter of 2003.
Contact lens sales were $675 million, up from $592 in 2003, the company said. Pharmaceutical sales increased $525 million from the year-ago period. B&L’s cataract and vitreoretinal division also posted sales gains, with $358 million in 2004, up from $328 million in the year-ago period.
The refractive surgery division showed decreased sales in the fourth quarter of 2004 compared with 2003, but overall for the year it showed an increase in sales to $152 million from $133 million in 2003.